Open AccessPB2079: INTERIM REPORT OF BENDAMUSTINE PLUS RITUXIMAB AS FIRST‐LINE INDUCTION THERAPY WITH OR WITHOUT LENALIDOMIDE MAINTENANCE THERAPY IN CHINESE PATIENTS WITH INHL OR EMCL: A MULTI‐CENTER PROSPECTIVE TRIAL
Author(s) -
Wang H.,
He Q.,
Zhao R.,
Xie L.,
Ma J.,
Liu C.,
Lu K.,
Wei H.,
Liu D.,
Xing L.,
Deng X.,
Sun Z.,
Chu X.,
Gao N.,
Zhong Y.,
Sun Y.,
Zhang H.,
Zhang H.,
Xu W.,
Li Z.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000851148.10454.66
Subject(s) - medicine , lenalidomide , maintenance therapy , rituximab , bendamustine , regimen , tolerability , interim analysis , oncology , neutropenia , clinical trial , surgery , adverse effect , toxicity , chemotherapy , lymphoma , multiple myeloma